泛昔洛韦联合重组牛碱性生长因子治疗生殖器疱疹的疗效及对T细胞亚群改变的影响

Efficacy of Famciclovir Combined with Recombinant Bovine Alkaline Growth Factor in Treatment of Genital Herpes and its Effects on T Cell Subsets

目的:探讨泛昔洛韦联合重组牛碱性生长因子治疗生殖器疱疹的疗效及对T细胞亚群改变的影响。方法:选取2015年8月至2018年1月首都医科大学附属北京同仁医院收治的生殖器疱疹患者104例,按照入院ID随机均分为对照组和观察组,每组52例。对照组患者给予泛昔洛韦治疗,观察组患者给予泛昔洛韦+重组牛碱性生长因子治疗。观察两组患者的临床疗效,治疗前后T细胞亚群指标水平、细胞因子[白细胞介素2(IL-2)、白细胞介素12(IL-12)及肿瘤坏死因子γ(TNF-γ)]水平,止痛、止疱及结痂时间,复发情况、不良反应发生情况。结果:观察组患者的总有效率为92.31%(48/52),明显高于对照组的76.92%(40/52),差异有统计学意义(P<0.05);治疗后,观察组患者CD3^+、CD4^+、CD8^+及CD4^+/CD8……+水平明显优于对照组,差异均有统计学意义(P<0.05);治疗后,观察组患者IL-2、IL-12及TNF-γ水平明显优于对照组,差异均有统计学意义(P<0.05);观察组患者的止痛、止疱和结痂时间明显短于对照组,差异均有统计学意义(P<0.05)。随访6个月,观察组患者的复发率为17.31%(9/52),明显低于对照组的44.23%(23/52),差异有统计学意义(P=0.000)。观察组、对照组患者的不良反应发生率分别为5.77%(3/52)、7.69%(4/52),差异无统计学意义(P=0.588)。结论:泛昔洛韦联合重组牛碱性生长因子治疗生殖器疱疹的效果理想,能够缩短止痛、止疱和结痂时间,提高免疫功能,且复发率较低。

OBJECTIVE: To probe into the efficacy of famciclovir combined with recombinant bovine alkaline growth factor in treatment of genital herpes and its effects on T cell subsets. METHODS: Totally 104 patients with genital herpes admitted into Beijing Tongren Hospital, Capital Medical University from Aug. 2015 to Jan. 2018 were extracted to be divided into the control group and the observation group via the admission ID, with 52 cases in each group. Patients in the control group were treated with famciclovir, while the observation group received famciclovir + recombinant bovine alkaline growth factor. The clinical efficacy, T cell subsets levels, cytokines [interleukin 2(IL-2), interleukin 12(IL-12), tumor necrosis factor γ(TNF-γ)] levels, pain relief, blisters and scarring time, recurrence, adverse drug reactions before and after treatment of two groups were observed. RESULTS: The total effective rate of the observation group was 92.31%(48/52), significantly higher than that of the control group [76.92%(40/52)], the difference was statistically significant(P<0.05). After treatment, the levels of CD3^+, CD4^+, CD8^+ and CD4^+/CD8^+ in the observation group were significantly better than those in the control group, and the differences were statistically significant(P<0.05). After treatment, the levels of IL-2, IL-12 and TNF-γ in the observation group were significantly better than those in the control group, and the differences were statistically significant(P<0.05). The analgesic, blistering and scarring time of the observation group were significantly shorter than the control group, and the difference was statistically significant(P<0.05). After six months of follow-up, the recurrence rate of the observation group was 17.31%(9/52), significantly lower than that of the control group [44.23%(23/52)], and the difference was statistically significant(P=0.000). The incidence of adverse drug reactions in the observation group and control group was 5.77%(3/52) and 7.69%(4/52), respectively, with no statistically significant difference(P=0.588). CONCLUSIONS: The efficacy of famciclovir combined with recombinant bovine alkaline growth factor in treatment of genital herpes is significant, which can shorten the time of pain relief, blistering and crusting, improve the immune function, and has lower recurrence rate.